Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx as...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions01:27

Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions

Nondepolarizing neuromuscular blockers prevent the membrane depolarization of muscle cells and inhibit muscle contraction. These are usually administered with anesthetics to achieve complete muscle relaxation. Upon administration, these drugs first block the small, rapidly contracting muscles of the face and hands, followed by the larger muscles of the trunk and the intercostal muscles. The diaphragm is the last muscle to be affected.
Although all competitive neuromuscular blockers are designed...
Disorders of the Skeletal Muscle01:28

Disorders of the Skeletal Muscle

The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ionized hypocalcemia in critically ill dogs.

Journal of veterinary internal medicine·2009
Same author

High microsatellite diversity and differential structuring among populations of the introduced common brushtail possum, Trichosurus vulpecula, in New Zealand.

Genetical research·2004
Same author

Comparison of transdermal fentanyl and intramuscular oxymorphone on post-operative behaviour after ovariohysterectomy in dogs.

Research in veterinary science·1999
Same author

Immunological and molecular characterization of three variant subtype P1.14 strains of Neisseria meningitidis.

Infection and immunity·1998
Same author

Strong ion difference approach to acid-base imbalances with clinical applications to dogs and cats.

The Veterinary clinics of North America. Small animal practice·1996
Same author

Evaluation of a hypertonic sodium chloride/dextran solution for treatment of traumatic shock in dogs.

Journal of the American Veterinary Medical Association·1996

Related Experiment Video

Updated: May 27, 2026

Stimulated Single Fiber Electromyography (SFEMG) for Assessing Neuromuscular Junction Transmission in Rodent Models
04:30

Stimulated Single Fiber Electromyography (SFEMG) for Assessing Neuromuscular Junction Transmission in Rodent Models

Published on: March 8, 2024

Anesthesia and myasthenia gravis.

L Blichfeldt-Lauridsen1, B D Hansen

  • 1Department of Anesthesiology, Sydvestjysk Sygehus Esbjerg, Denmark. louise@blichfeldtnet.dk

Acta Anaesthesiologica Scandinavica
|November 19, 2011
PubMed
Summary
This summary is machine-generated.

Anesthesia for myasthenia gravis (MG) patients is safe with careful planning. Optimal perioperative management, including pyridostigmine and monitoring, avoids respiratory complications for MG patients.

More Related Videos

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
07:09

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice

Published on: September 8, 2011

Related Experiment Videos

Last Updated: May 27, 2026

Stimulated Single Fiber Electromyography (SFEMG) for Assessing Neuromuscular Junction Transmission in Rodent Models
04:30

Stimulated Single Fiber Electromyography (SFEMG) for Assessing Neuromuscular Junction Transmission in Rodent Models

Published on: March 8, 2024

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice
07:09

Subcutaneous Administration of Muscarinic Antagonists and Triple-Immunostaining of the Levator Auris Longus Muscle in Mice

Published on: September 8, 2011

Area of Science:

  • Anesthesiology
  • Neurology

Background:

  • Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions, leading to muscle weakness.
  • MG incidence and prevalence are rising, yet it remains underdiagnosed, posing challenges for anesthesiologists.
  • Post-surgical respiratory failure is a significant concern in myasthenic patients.

Purpose of the Study:

  • To review and update anesthesiologists on optimal perioperative management strategies for myasthenia gravis patients.
  • To highlight safe anesthetic techniques and considerations for managing MG patients undergoing surgery.

Main Methods:

  • Literature review using PubMed with keywords: myasthenia gravis, neuromuscular blocking agents, sevoflurane, epidural, neuromuscular blockade reversal, and pyridostigmine.
  • Inclusion of English-language reviews and clinical trials.

Main Results:

  • Myasthenia gravis patients can undergo anesthesia safely with general anesthesia or peripheral nerve blocks.
  • Avoiding neuromuscular blocking agents or using them in reduced doses with careful monitoring is recommended.
  • Volatile anesthesia or epidural techniques can facilitate safe anesthesia in MG patients.

Conclusions:

  • Thorough pre-operative evaluation is crucial for managing myasthenia gravis patients.
  • Continuing pyridostigmine and implementing careful monitoring ensures safe perioperative care.
  • Anesthesia for myasthenia gravis patients can be managed effectively without the need for post-operative mechanical ventilation.